HRMY - Harmony Biosciences Holdings, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Plymouth Meeting,
United States
Type: Equity
HRMY price evolution
HRMY
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $317.3 | $332.98 | $311.66 | |
| Short term investments | $29.61 | $39.37 | $41.8 | |
| Net receivables | $81.5 | $83.16 | $79.72 | $74.14 |
| Inventory | $6.92 | $5.64 | $5.86 | $5.36 |
| Total current assets | $522.4 | $458.34 | $479.5 | $451.07 |
| Long term investments | $87.45 | $81.51 | $72.44 | |
| Property, plant & equipment | $3.07 | $0.75 | $0.21 | $0.37 |
| Goodwill & intangible assets | $125.19 | $131.15 | $137.11 | |
| Total noncurrent assets | $400.04 | $367.48 | $360.38 | |
| Total investments | $117.06 | $120.88 | $114.24 | |
| Total assets | $928.13 | $858.38 | $846.99 | $811.45 |
| Current liabilities | ||||
| Accounts payable | $10.53 | $22.68 | $15.14 | $17.73 |
| Deferred revenue | ||||
| Short long term debt | $15 | $15 | $15 | |
| Total current liabilities | $161.28 | $146.58 | $154.25 | $163.78 |
| Long term debt | $167.85 | $171.42 | $175 | $178.57 |
| Total noncurrent liabilities | $173.22 | $177.34 | $180.68 | |
| Total debt | $186.42 | $190 | $193.57 | |
| Total liabilities | $331.33 | $319.8 | $331.59 | $344.46 |
| Shareholders' equity | ||||
| Retained earnings | -$47.26 | -$93.35 | -$104.94 | -$143.28 |
| Other shareholder equity | $0.5 | -$0.23 | -$0.17 | $0 |
| Total shareholder equity | $538.58 | $515.39 | $466.99 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $311.66 | $243.78 | $234.31 | $228.63 |
| Short term investments | $41.8 | $79.33 | ||
| Net receivables | $74.14 | $54.74 | $34.84 | $22.18 |
| Inventory | $5.36 | $4.3 | $4.43 | $3.82 |
| Total current assets | $451.07 | $400.29 | $284.44 | $262.89 |
| Long term investments | $72.44 | $23.32 | $0.75 | $0.75 |
| Property, plant & equipment | $0.37 | $2.88 | $0.82 | $0.94 |
| Goodwill & intangible assets | $137.11 | $160.95 | $143.92 | $162.34 |
| Total noncurrent assets | $360.38 | $273.58 | $149 | $164.18 |
| Total investments | $114.24 | $102.65 | $0.75 | $0.75 |
| Total assets | $811.45 | $673.87 | $433.44 | $427.07 |
| Current liabilities | ||||
| Accounts payable | $17.73 | $3.79 | $1 | $2.56 |
| Deferred revenue | ||||
| Short long term debt | $15 | $2 | $2 | |
| Total current liabilities | $163.78 | $78.88 | $53.77 | $134.54 |
| Long term debt | $178.57 | $189.65 | $189.98 | $194.25 |
| Total noncurrent liabilities | $180.68 | $192.15 | $193.16 | $195.35 |
| Total debt | $193.57 | $191.65 | $191.98 | $194.25 |
| Total liabilities | $344.46 | $271.03 | $246.94 | $329.89 |
| Shareholders' equity | ||||
| Retained earnings | -$143.28 | -$272.13 | -$453.6 | -$488.19 |
| Other shareholder equity | $0 | -$0.15 | ||
| Total shareholder equity | $466.99 | $402.84 | $186.51 | $97.18 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $172.81 | $154.62 | $168.41 | |
| Cost of revenue | $32.14 | $27.48 | $43.15 | |
| Gross Profit | $140.67 | $127.13 | $125.26 | |
| Operating activities | ||||
| Research & development | $63.58 | $22.19 | $30.31 | |
| Selling, general & administrative | $55.73 | $52.91 | $54.76 | |
| Total operating expenses | $119.31 | $75.1 | $85.06 | |
| Operating income | $21.36 | $52.03 | $40.2 | |
| Income from continuing operations | ||||
| EBIT | $26.1 | $56.32 | $55.12 | |
| Income tax expense | $10.1 | $13.45 | $13.08 | |
| Interest expense | $4.4 | $4.54 | $15.43 | |
| Net income | ||||
| Net income | $11.59 | $38.33 | $26.61 | |
| Income (for common shares) | $11.59 | $38.33 | $26.61 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $582.02 | $437.86 | $305.44 | $159.74 |
| Cost of revenue | $121.24 | $83.48 | $55.52 | $27.74 |
| Gross Profit | $460.79 | $354.37 | $249.92 | $132 |
| Operating activities | ||||
| Research & development | $76.06 | $70.89 | $30.37 | $19.45 |
| Selling, general & administrative | $192.69 | $163.3 | $132.03 | $95.57 |
| Total operating expenses | $268.76 | $234.19 | $162.39 | $115.02 |
| Operating income | $192.03 | $120.19 | $87.53 | $16.99 |
| Income from continuing operations | ||||
| EBIT | $197.15 | $120.36 | $61.4 | -$8.72 |
| Income tax expense | $44.54 | -$76.78 | $2.83 | |
| Interest expense | $23.76 | $15.67 | $23.97 | $28.22 |
| Net income | ||||
| Net income | $128.85 | $181.47 | $34.6 | -$36.94 |
| Income (for common shares) | $128.85 | $181.47 | $34.6 | -$63.85 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $11.59 | $38.33 | $26.61 | |
| Operating activities | ||||
| Depreciation | $6.05 | $6.12 | $6.13 | |
| Business acquisitions & disposals | -$33.07 | -$36.97 | ||
| Stock-based compensation | $10.96 | $10.43 | $8.89 | |
| Total cash flows from operations | $42.62 | $31.14 | $76.67 | |
| Investing activities | ||||
| Capital expenditures | -$0.63 | -$0.01 | -$0.11 | |
| Investments | $4.34 | -$6.18 | $1.01 | |
| Total cash flows from investing | -$60.3 | -$54.86 | -$6.19 | -$36.06 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.57 | $0.12 | -$49.77 | |
| Net borrowings | -$3.75 | -$3.75 | -$3.75 | |
| Total cash flows from financing | -$8.26 | -$3.45 | -$3.63 | -$53.52 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $75.71 | -$15.69 | $21.32 | -$12.92 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $128.85 | $181.47 | $34.6 | -$36.94 |
| Operating activities | ||||
| Depreciation | $24.36 | $23.39 | $18.84 | $10.24 |
| Business acquisitions & disposals | -$36.97 | -$40 | -$100 | -$2 |
| Stock-based compensation | $31.21 | $26.91 | $16.11 | $5.19 |
| Total cash flows from operations | $219.39 | $144.47 | $98.56 | -$2.98 |
| Investing activities | ||||
| Capital expenditures | -$0.31 | -$0.17 | -$0.3 | -$0 |
| Investments | -$9.16 | -$101.66 | ||
| Total cash flows from investing | -$46.44 | -$141.83 | -$100.3 | -$2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$94.94 | $8.84 | $39.07 | $147.76 |
| Net borrowings | -$10.09 | -$2 | -$31.65 | $73.61 |
| Total cash flows from financing | -$105.55 | $6.84 | $7.42 | $209.16 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $67.4 | $9.47 | $5.68 | $204.17 |
News
Fundamentals
| Market cap | $1.77B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 57.03M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.74 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.24 |
| Quick ratio | 3.20 |